Nine Masts Capital’s Summit Therapeutics SMMT Stock Holding History

Nine Masts Capital’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$474K	Buy	+28,037	New	+$419K	0.06%	121

Other funds holding SMMT

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Simplify Asset Management Las Vegas, Nevada $6.11B AUM 3.71% 1-Year Est. Return

Hohimer Wealth Management Seattle, Washington $1.03B AUM 25.45% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Nine Masts Capital's SMMT Position: Q3 2026 in Review

Nine Masts Capital opened a new position in Summit Therapeutics (SMMT) in Q3 2026: 28,037 shares worth $474K. The stake represents 0.06% of the portfolio and ranks #121 among its holdings.

141 funds tracked by Wall St. Rank hold SMMT as of Q3 2026.

Nine Masts Capital held 28,037 shares of Summit Therapeutics worth $474K as of Q3 2026.
Summit Therapeutics was a new Nine Masts Capital position in Q3 2026.
Summit Therapeutics made up 0.06% of Nine Masts Capital's portfolio in Q3 2026, its #121 holding.
141 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2026.

Based on Nine Masts Capital's 13F filing for Q3 2026, filed 9 Nov 2026.